Use of biorelevant dissolution media in dissolution tests as a predictive method of oral bioavailability
DOI:
https://doi.org/10.1590/s2175-97902022e19759%20Palavras-chave:
Dissolution profile, Biorelevant media, Human gastrointestinal fluids, Pharmacopoeia mediaResumo
Dissolution is a key step in the uptake of oral drugs. In order to compare the behaviour of the dissolution of two formulations, the dissolution profile test was used. This assay must be discriminative and should mimic in vivo conditions. Many dissolution media described in pharmacopoeias are not predictive of bioavailability. Due to this, biorelevant media are used as an alternative to solve this problem. The objective of this work is to evaluate the relevance of biorelevant dissolution media to predict in vivo drug dissolution. For this, a bibliographic search was carried out in scientific databases. The search was first performed for articles verifying the physicochemical properties of human gastrointestinal fluids. Subsequently, a comparison was made between the properties of gastrointestinal fluids and those of biorelevant and pharmacopoeial media. Finally, the results of bioequivalence studies and dissolution profile tests in biorelevant media described in the literature were compared. The results revealed that there are a few publications that have analysed some physicochemical properties of gastrointestinal fluids. In addition, high variability was observed for some properties. Regarding the comparison of these properties with pharmacopoeial media and biorelevant media, the analysis showed that the biorelevant media are more similar to gastrointestinal fluids than the pharmacopoeial media. Finally, the in vitro dissolution profile results were similar to the results obtained in vivo. Thus, biorelevant media may be useful for analysing dissolution profiles.
Downloads
Referências
Abeele JVD, Rubbens J, Browers J, Augustijns P. The dynamic gastric environment and its impact on drug ande formulation behaviour. Eur J Pharm Sci. 2017;96:207-31.
Agência Nacional de Vigilância Sanitária (Brasil). Resolução-RE n° 1.170, de 19 de abril de 2006. Determina a publicação do Guia para provas de biodisponibilidade relativa/bioequivalência de medicamentos. Diário Oficial da União 24 abr. 2006; Seção 1.
Agência Nacional de Vigilância Sanitária (Brasil). Resolução-RDC n° 37, de 06 de julho de 2009. Trata da admissibilidade das Farmacopeias estrangeiras. Diário Oficial da União 08 jul. 2009; Seção 1.
Agência Nacional de Vigilância Sanitária (Brasil). Resolução-RDC n° 31, de 11 de agosto de 2010. Dispõe sobre a realização dos Estudos de Equivalência Farmacêutica e de Perfil de Dissolução Comparativo. Diário Oficial da União 12 ago. 2010; Seção 1.
Agência Nacional de Vigilância Sanitária (Brasil). Resolução-RDC n° 37, de 03 de agosto de 2011. Dispõe sobre o Guia para isenção e substituição de estudos de biodisponibilidade relativa/bioequivalência e dá outras providências. Diário Oficial da União 04 ago. 2011; Seção 1.
Agência Nacional de Vigilância Sanitária (Brasil). Resolução-RDC n° 73, de 07 de abril de 2016. Dispõe sobre mudanças pós-registro, cancelamento de registro de medicamentos com princípios ativos sintéticos e semissintéticos e dá outras providências. Diário Oficial da União 08 abr. 2016; Seção 1.
Agência Nacional de Vigilância Sanitária (Brasil). Resolução-RDC n° 166, de 24 de julho de 2017. Dispõe sobre a validação de métodos analíticos e dá outras providências. Diário Oficial da União 25 jul. 2017; Seção 1.
Almukainzi M, Bou-Chacra NA, Walker RB, Lobenberg R. Biorelevant dissolution testing. In: Therapeutic Delivery Solutions. 1 st ed. John Wiley & Sons; 2014. p.335-365.
Amidon GL, Lennernãs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
Andreas CJ, Tomaszewka I, Muenster U, Mey D, Mueck W, Dressman JB. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine. Eur J Pharm Biophar. 2016;105:193-202.
Annaert P, Brouwers J, Bijnens A, Lammert F, Tack J, Augustijns P. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. Eur J Pharm Sci . 2010;39(1-3):15-22.
Armand P, Borel P, Pasquier B, Dubois C, Sentf M, Andre M, et al. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am J Physiol. 1996;271(1):172-183.
Ashford M. O trato gastrointestinal - fisiologia e absorção de fármacos. In: Delineamento de formas farmacêuticas. 2 nd ed. Artmed. 2005. p. 230-244.
Baxevanis F, Kuiper J, Fotaki N. Fed-state gastric media and drug analysis techniques: Current status and points to consider. Eur J Pharm Biopharm. 2016;107:234-48.
Bergstrom CA, Holm R, Jorgensen SA, Andersson SB, Artursson P, Beato S, et al. Early pharmaceutical profiling to predict oral drug absortion current status and unmet needs. Eur J Pharm Sci . 2014;57:173-99.
Browers J, Tack J, Lammert F, Augustijs P. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J Pharm Sci. 2006;95(2):372-83.
Campos DR. Avaliação in vitro - in vivo de duas formulações de pantoprazol: estudos farmacocinéticos e perfis de dissolução em meios biorrelevantes. [Master’s dissertation]. São Paulo: Faculdade de Ciências Médicas, Universidade Estadual de Campinas; 2008.
Charman WN, Rogge MC, Boddy AW, Barr WH, Berger BM. Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single and double peak phenomena in the plasma profiles. J Clin Pharmacol. 1993;33(12):1207-13.
Chiann C. Correlação linear e regressão linear simples. In: Biofarmacotécnica. Rio de Janeiro: Guanabara Koogan Ltda. 2009. p.272-280.
Clarysse S, Tack J, Lammert F, Duchateau G, Reppas C, Augustijs P. Postprandial evolution in composition characteristics of human duodenal fluids in different nutritional states. J Pharm Sci. 2009;98(3):1177-92.
Dahan AS, Amidon GL. Gastrointestinal dissolution and absorption of Class II Drugs. In: Drug bioavailability, estimation of solubility, permeability, absorption and bioavailability. 2 nd ed. Wiley-VCH. 2009. p. 33 - 51.
De Spiegeler B, Baert B, Vangheluwe E, Becue I, Smet JD, Spanoghe P, et al. Comparison of the wetting properties of three commonly used simulated intestinal fluids used as dissolution media in the characterization of drugs. J Solution Chem. 2007;36(7):835-43.
Diakidou A, Vertzoni M, Goumas K, Soderlind E, Abrahamsson B, Dressman J, et al.Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res . 2009;26(9):2141-51.
Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absortion: immediate release dosage forms. Pharm Res . 1998;15(1):11-22.
Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci . 2000;2:73-80.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), guideline on the investigation of bioequivalence. London: European Medicines Agency. 2010. 27 p.
Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29(8):1035-41.
Fadda HM, Sousa T, Carlsson AS, Abrahamsson B.; Williams JG, Kumar D, et al. Drug solubility in luminal fluids from different regions of the small and large intestine humans. Mol Pharm. 2010;07(5):1527-32.
Farmacopeia Brasileira. 5a ed. Brasília: Agência Nacional de Vigilância Sanitária. 2010.
Foltz E, Azad S, Everett ML, Holznecht, ZE, Sanders NL, Thompson JW. An assessment of human gastric fluid composition as a function of PPI usage. Physiol Rep. 2015;3(1):01-13.
Food and Drug Administration. FDA. Draft guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2015. 17 p.
Fotaki N, Vertzoni M. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations. The Open Drug Deliv J. 2010;4(1):02-13.
Gisolfi CV, Summers RW, Lambert GP, Xia T. Effect of beverage osmolality on intestinal fluid absorption during exercise. J Appl Physiol. 1998;85(5):1941-48.
Grignard E, Taylor R, Mcallister M, Box K, Fotaki N . Considerations for the development of in vitro dissolution tests to reduce or replace preclinical oral absorption studies. Eur J Pharm Sci . 2016;99:193-201.
Holmstock N, De Bruyn T, Bevernage J, Annaert P, Mols R, Tack J, et al. Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. Eur J Pharm Sci . 2013;49(1):27-32.
Honório TS, Pinto EC, Rocha HVA, Esteves VSD, Santos TC, Castro HCR, et al. In vitro-in vivo correlation of efavirenz tablets using GastroPlus® AAPS PharmSciTech. 2013;14(3):1244-54.
Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46(1-3):75-87.
Jantratid E, Janssen N, Reppas C, Dressman JB . Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res . 2008;25(7):1663-76.
Jones HM, Parrott N., Ohlenbusch G, Lavé T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modeling. Clin Pharmacokinet. 2006;45(12):1213-26.
Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB , Reppas C .Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res . 2006a;23(1):165-76.
Kalantzi L , Persson E, Polentarutti B, Abrahamsson B , Goumas K , Dressman JB , et al. Canine intestinal contents vs. simulated media for the assessment solubility of two weak bases in the human small intestinal contents. Pharm Res . 2006b;23(6):1373-81.
Klein, S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12(3):397-06.
Koziolek M, Garbacz G, Neumann M, Weitschies W. Simulating the postprandial stomach: biorelevant test methods for the estimation of intragastric drug dissolution. Mol Pharm . 2013;10(6):2211-21.
Linddahl, A, Ungell AL, Knutson L, Lennernãs H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res . 1997;14(4):497-02.
Litou C, Vertzoni M , Goumas C, Vasdekis V, Xu W, Kesisoglou F, et al. Characteristics of the human upper gastrointestinal contents in the fasted state under hypo- and A-chlorhydric gastric conditions under conditions of typical drug - drug interaction studies. Pharm Res . 2016;33(6):1399-12.
Lu PJ, Hsu PI, Chen CH, Hsiao M.; Chang WC, Tseng HH. Gastric juice acidity in upper gastrointestinal diseases. World J Gastroenterol. 2010;16(43):5496-01.
Perez de La Cruz Moreno M, Oth M, Deferme S, Lammert F, Tack J , Dressman JP, et al. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol. 2006;58(8):1079-89.
Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm . 2010;7(5):1388-405.
Pedersen BL, Mullertz A, Brondsted H, Kristensen HG. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm Res . 2000;17(7):891-94.
Pedersen PB, Vilmann P, Bar-Shalom D, Mullertz A , Baldursdottir S. Characterization of fasted human gastric fluid for relevant rheological parameters and gastric lipase activities. Eur J Pharm Biophar m. 2013;85(3):958-65.
Persson E M, Gustafsson A, Carlsson AS , Nilsson RG, Knutson L , Forsell, et al . The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res . 2005;22(12):2141-51.
Rabie SC, Flanagan T, Martin PD, Basit AW. Inter-subject variability in intestinal drug solubility. Int J Pharm. 2015;485(1-2):229-234.
Riethorst D, Mols R , Duchateau G, Tack J , Brouwers J, Augustijns. Characterization of human duodenal fluids in fasted and fed state conditions. J Pharm Sci. 2016;105(2):673-681.
Rudolph MW, Klein S, Beckert TE, Petereit HU, Dressman JB . A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001;51(3):183-90.
Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH. Dosage form-related food interaction observed in a marketed oncedaily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol. 2002;58(2):119-25.
Stippler E, Kopp S, Dressman JB . Comparison of US pharmacopeia simulated intestinal fluid TS (without pancreatin) and phosphate standard buffer pH 6,8, TS of the international pharmacopeia with respect to their use in vitro dissolution testing. Dissolut Technol. 2004;11(2):06-10.
Vertzoni M , Dressman J, Butler J, Hempenstall J, Reppas C . Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm. 2005;60(3):413-17.
Wei H, Lobenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur J Pharm Sci . 2006;29(1):45-52.
World Health Organization WHO. Multisource (generic) pharmaceutical products: guidelines registration requirements to establish interchangeability. In: WHO Expert Committee on Specifications for Pharmaceutical Products: fortieth report. Geneva: World Health Organization; 2006. 54 p.
Wuyts B, Brouwers J , Mols R , Tack J , Annaert P , Augustijns P. Solubility profiling of HIV protease inhibitors in human intestinal fluids. J Pharm Sci. 2013;102(10):3800-07.
Wuyts B , Riethorst D , Brouwers J , Tack J , Annaert P , Augustijns P. Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. Int J Pharm. 2015;478(2):736-44.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
